PranaX's Licensed Exosome Manufacturing Technology Demonstrates Safety in Phase I Pancreatic Cancer Trial
核心洞察
PranaX Corporation (搜索) announced that a study featuring their exclusively licensed exosome manufacturing technology from MD Anderson Cancer Center was published in Nature Communications.
The phase I clinical trial testing engineered exosomes (搜索) with KRASG12D (搜索)-specific siRNA in pancreatic cancer (搜索) showed no serious adverse events, even at escalated doses.
PranaX holds exclusive licensing rights for non-cancer indications of this validated manufacturing platform, which they plan to combine with their regenerative medicine technology.
PranaX Corporation (搜索) has announced that a clinical study featuring their exclusively licensed exosome manufacturing technology was published in Nature Communications, marking a significant milestone for the biotechnology company's regenerative medicine platform. The study, led by scientific co-founders Valerie S. Kalluri, MD/PhD, MBA and Raghu Kalluri MD/PhD, demonstrated the safety profile of engineered exosomes (搜索) in human subjects.
Clinical Trial Results Show Safety Profile
The published study, titled "Engineered exosomes (搜索) with KRASG12D (搜索) specific siRNA in pancreatic cancer (搜索): a phase I study with immunological correlates," evaluated the safety of engineered exosomes targeting the KRASG12D mutation in pancreatic cancer patients. The FDA-approved clinical trial showed no serious adverse events, even when doses were escalated, providing crucial safety data for exosome-based therapeutic approaches.
"The study shows that our licensed technology is safe in an FDA approved clinical trial with no serious adverse events, even at escalated doses, affirming our belief in the science and safety of exosomes (搜索)," said Steven J. Greco, PhD, Founder and Chief Strategy Officer of PranaX Corporation (搜索).
Exclusive Licensing Agreement for Non-Cancer Applications
PranaX has secured exclusive licensing rights from The University of Texas MD Anderson Cancer Center for the exosome manufacturing technology in non-cancer indications. This proprietary platform, originally developed at MD Anderson, will serve as the foundation for PranaX's regenerative medicine applications, combining with their in-house technology to advance exosome-based therapeutics.
The licensing agreement positions PranaX to leverage this validated manufacturing platform for exosome engineering and future therapeutic applications outside of oncology. The company plans to focus on regenerative medicine solutions using mesenchymal stem cell (MSC)-derived exosomes (搜索).
Strategic Implications for Regenerative Medicine
Chief Executive Officer Phillip Maderia emphasized the significance of the safety data for the company's development pipeline. "This study demonstrates that our licensed technology has proven safe in an initial human study, a critical milestone in the development of exosome-based therapeutics," Maderia stated. "This achievement underscores PranaX's commitment to advancing our MSC-derived exosome platform and harnessing its potential to support wellness and help individuals live healthier, more fulfilling lives."
The publication in Nature Communications provides peer-reviewed validation of the manufacturing technology's safety profile, which PranaX considers essential for advancing their regenerative medicine applications. The company operates from the Levit Green life science campus in Houston, Texas, where they conduct research, development, and manufacturing operations focused on stem cell-derived exosomes (搜索) through evidence-based science.